Suppr超能文献

促红细胞生成性原卟啉异二聚体铁螯合酶的产生与特性分析

Production and characterization of erythropoietic protoporphyric heterodimeric ferrochelatases.

作者信息

Najahi-Missaoui Wided, Dailey Harry A

机构信息

Biomedical and Health Sciences Institute, University of Georgia, A222 Life Sciences Bldg, Athens GA 30602, USA.

出版信息

Blood. 2005 Aug 1;106(3):1098-104. doi: 10.1182/blood-2004-12-4661. Epub 2005 Apr 14.

Abstract

Mutations resulting in diminished activity of the dimeric enzyme ferrochelatase are a prerequisite for the inherited disorder erythropoietic protoporphyria (EPP). Patients with clinical EPP have only 10% to 30% of normal levels of ferrochelatase activity, and although many patients with EPP have one mutant allele and one "low-expression" normal allele, the possibility remains that, for some, low ferrochelatase activity may result from an EPP mutation that has an impact on both subunits of the wild-type/mutant heterodimer. Here we present data for 12 ferrochelatase wild-type/EPP mutant heterodimers showing that some mutations result in heterodimers with the residual activity anticipated from individual constituents, whereas others result in heterodimers with significantly lower activity than would be predicted. Although the data do not allow an a priori prediction of heterodimeric residual activity based solely on the in vitro activity of EPP homodimers or the position of the mutated residue within ferrochelatase, mutations that affect the dimer interface or [2Fe-2S] cluster have a significantly greater impact on residual activity than would be predicted. These data suggest that some EPP mutations may result in clinically overt EPP in the absence of a low-expression, wild-type allele; this is of potential significance for genetic counseling of patients with EPP.

摘要

导致二聚体酶铁螯合酶活性降低的突变是遗传性疾病红细胞生成性原卟啉症(EPP)的先决条件。临床EPP患者的铁螯合酶活性仅为正常水平的10%至30%,尽管许多EPP患者有一个突变等位基因和一个“低表达”正常等位基因,但对于一些患者来说,铁螯合酶活性低仍有可能是由一个对野生型/突变型异二聚体两个亚基都有影响的EPP突变导致的。在此,我们展示了12种铁螯合酶野生型/EPP突变型异二聚体的数据,表明一些突变导致的异二聚体具有单个成分预期的残余活性,而其他突变导致的异二聚体活性明显低于预期。尽管这些数据不允许仅基于EPP同二聚体的体外活性或铁螯合酶内突变残基的位置对异二聚体残余活性进行先验预测,但影响二聚体界面或[2Fe-2S]簇的突变对残余活性的影响比预期的要大得多。这些数据表明,一些EPP突变可能在没有低表达野生型等位基因的情况下导致临床上明显的EPP;这对EPP患者的遗传咨询具有潜在意义。

相似文献

5
Biochemical abnormality in erythropoietic protoporphyria: cause and consequences.红细胞生成性原卟啉症的生化异常:原因与后果
J Pediatr Gastroenterol Nutr. 2006 Jul;43 Suppl 1:S36-40. doi: 10.1097/01.mpg.0000226388.56612.fa.
8
Erythropoietic protoporphyria.红细胞生成性原卟啉症。
Orphanet J Rare Dis. 2009 Sep 10;4:19. doi: 10.1186/1750-1172-4-19.

引用本文的文献

1
New Avenues of Heme Synthesis Regulation.新的血红素合成调控途径。
Int J Mol Sci. 2022 Jul 5;23(13):7467. doi: 10.3390/ijms23137467.
3
Small-molecule inhibitors of ferrochelatase are antiangiogenic agents.亚铁螯合酶的小分子抑制剂是血管生成抑制剂。
Cell Chem Biol. 2022 Jun 16;29(6):1010-1023.e14. doi: 10.1016/j.chembiol.2022.01.001. Epub 2022 Jan 31.
9
Metal ion substrate inhibition of ferrochelatase.金属离子底物对亚铁螯合酶的抑制作用
J Biol Chem. 2008 Aug 29;283(35):23685-91. doi: 10.1074/jbc.M803372200. Epub 2008 Jul 1.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验